Oral paclitaxel bests IV version for tumor response, neuropathy incidence in mBC

SAN ANTONIO – An oral formulation of paclitaxel given with the P-glycoprotein pump inhibitor encequidar improved outcomes and reduced neuropathy risk, compared with intravenous paclitaxel in a phase 3 trial.

Read the full article here

Related Articles